The varenicline group had significantly higher continuous abstinence rates vs the placebo group during weeks @ through @ ( @ % for the varenicline group vs @ % for the placebo group ; RD , @ % -LSB- @ % CI , @ % -@ % -RSB- ; RR , @ -LSB- @ % CI , @-@ @ -RSB- ) and weeks @ through @ ( @ % for the varenicline group vs @ % for the placebo group ; RD , @ % -LSB- @ % CI , @ % -@ % -RSB- ; RR , @ -LSB- @ % CI , @-@ @ -RSB- ) .